Abstract
In COVID-19 patients, abnormal blood clotting is common, characterized by elevated D-dimer and fibrinogen levels, reduced platelets, and prolonged clotting times. The second week of infection can trigger a cytokine storm, marked by heightened proinflammatory Interleukin-6 (IL-6) levels, associated with Acute Respiratory Distress Syndrome (ARDS) and organ failure. This study compared hematological biomarkers, D-dimer, and IL-6 in moderate and severe COVID-19 cases. In a cross-sectional study, 81 patients meeting inclusion criteria were examined at a leading private COVID-19 referral hospital in Malang Regency. Data from clinical records and lab results encompassing blood counts, D-dimer, and IL-6 levels were collected. D-dimer was assessed through immunoturbidimetry (STA-Procoag-PPL, Diagnostica Stago S.A.S.), while IL-6 was measured using a chemiluminescent immunoassay (Cobas e411 Elecsys, Roche). Data distribution normality was assessed using Kolmogorov-Smirnov and Shapiro-Wilk tests. Non-normally distributed data were analyzed using the Mann-Whitney U test for numerical data and the Fisher exact test for comorbidity-severity correlation. Moderate COVID-19 cases disproportionately affected females, while severe cases had an even gender distribution. The median age was comparable, but mild cases were typically younger. Hemoglobin, hematocrit, leukocyte, neutrophil, platelet, and procalcitonin levels were normal in both groups, with lowered lymphocyte counts. Severe cases displayed a higher Neutrophil-to-Lymphocyte Ratio (NLR). D-dimer and IL-6 were significantly elevated in extreme cases. This study underscores potential gender and age-related discrepancies in COVID-19 severity, emphasizing the significance of monitoring specific blood parameters for disease progression indicators. Further investigation is vital to unveil underlying mechanisms and clinical implications, aiding the management of COVID-19 patients.
Reference41 articles.
1. Kementerian Kesehatan Republik Indonesia. Situasi terkini perkembangan Coronavirus Disease (COVID-19), Januari 2023. Available from: https://infeksiemerging.kemkes.go.id/dashboard/covid-19 (accessed February 03, 2023).
2. Kementerian Kesehatan Republik Indonesia, 2020. Pedoman pencegahan dan pengendalian Coronavirus Disease (COVID-19). Sub-direktorat Penyakit Infeksi Emerging, Direktorat Surveilans dan Karantina Kesehatan, Direktorat Jenderal Pencegahan dan Pengendalian Penyakit, Kementerian Kesehatan RI. Available from: https://infeksiemerging.kemkes.go.id (accessed 2 January 02, 2021).
3. Kementerian Kesehatan Republik Indonesia. Situasi terkini perkembangan Coronavirus Disease (COVID-19), April 2021. Available from: https://infeksiemerging.kemkes.go.id/situasi-infeksi-emerging/situasi-terkini-perkembangan-coronavirus-disease-covid-19-18-april-2021 (accessed May 21, 2021).
4. Pathogenesis, diagnosis, and treatment of hemostatic disorders in COVID-19 patients;Khalirakhmanov;Acta Naturae,2021
5. Modulation of hemostasis in COVID-19; Blood platelets may be important pieces in the COVID-19 puzzle;Ulanowska;Pathogens,2021